The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing

Biochemical and Biophysical Research Communications

Volumn 338, Issue 1, 2005, Pages 627-638

  Kaelin Jr , William G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

EglN; FIH 1; Hemangioblastoma; HIF; Hydroxylation; Kidney cancer; Oxygen; Pheochromocytoma; Succinate dehydrogenase; Von Hippel Lindau

Indexed keywords

ASPARAGINE; DIMER; FG 0041; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR ANTAGONIST; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXYGENASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; POLYAMIDE; PROTEIN INHIBITOR; SORAFENIB; SUNITINIB; THIOREDOXIN 1 INHIBITOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2 INHIBITOR; VON HIPPEL LINDAU PROTEIN;

ADAPTATION; ALPHA CHAIN; BETA CHAIN; CANCER; CARBOXY TERMINAL SEQUENCE; CEREBROVASCULAR DISEASE; GENE MUTATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HEMANGIOBLASTOMA; HUMAN; HYDROXYLATION; KIDNEY CARCINOMA; NONHUMAN; OXYGEN SENSING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TISSUE OXYGENATION; VON HIPPEL LINDAU DISEASE;

MAMMALIA;

EID: 27544477748     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.08.165     Document Type: Review

References (196)

1. E.T. Collins Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes) Trans. Ophthal. Soc. UK 14 1894 141 149
2. A. Lindau Zur frage der angiomatosis retinae und ihrer hirncomplikation Acta Opthal. 4 1927 193 226
3. E. von Hippel Ueber eine sehr seltene erkrankung der nethaut Graefe Arch. Ophthal. 59 1904 83 106
4. E. Maher, and W.G. Kaelin von Hippel-Lindau disease Medicine 76 1997 381 391
5. B.R. Seizinger, G.A. Rouleau, L.J. Ozelius, A.H. Lane, G.E. Farmer, J.M. Lamiell, J. Haines, J.W.M. Yuen, D. Collins, D. Majoor-Krakauer, T. Bonner, C. Mathew, A. Rubenstein, J. Halperin, A. McConkie-Rosell, J.S. Green, J.A. Trofatter, B.A. Ponder, L. Eierman, M.I. Bowmer, R. Schimke, B. Oostra, N. Aronin, D.I. Smith, H. Drabkin, M.H. Waziri, W.J. Hobbs, R.L. Martuza, P.M. Conneally, Y.E. Hsia, and J.F. Gusella Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma Nature 332 1988 268 269
6. F. Latif, K. Tory, J. Gnarra, M. Yao, F.-M. Duh, M.L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil, L. Schmidt, F. Zhou, H. Li, M.H. Wei, F. Chen, G. Glenn, P. Choyke, M.M. Walther, Y. Weng, D.-S.R. Duan, M. Dean, D. Glavac, F.M. Richards, P.A. Crossey, M.A. Ferguson-Smith, D.L. Pasiler, I. Chumakov, D. Cohen, A.C. Chinault, E.R. Maher, W.M. Linehan, B. Zbar, and M.I. Lerman Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1993 1317 1320
7. W.Y. Kim, and W.G. Kaelin Role of VHL gene mutation in human cancer J. Clin. Oncol. 22 2004 4991 5004
8. A. Schoenfeld, E. Davidowitz, and R. Burk A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor Proc. Natl. Acad. Sci. USA 195 1998 8817 8822
9. O. Iliopoulos, M. Ohh, and W. Kaelin pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation Proc. Natl. Acad. Sci. USA 95 1998 11661 11666
10. C. Blankenship, J. Naglich, J. Whaley, B. Seizinger, and N. Kley Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity Oncogene 18 1999 1529 1535
11. O. Iliopoulos, A. Kibel, S. Gray, and W.G. Kaelin Tumor suppression by the human von Hippel-Lindau gene product Nature Medicine 1 1995 822 826
12. J.R. Gnarra, S. Zhou, M.J. Merrill, J. Wagner, A. Krumm, E. Papavassiliou, E.H. Oldfield, R.D. Klausner, and W.M. Linehan Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product Proc. Natl. Acad. Sci. USA 93 1996 10589 10594
13. A. Kibel, O. Iliopoulos, J.D. DeCaprio, and W.G. Kaelin Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C Science 269 1995 1444 1446
14. K.M. Lonergan, O. Iliopoulos, M. Ohh, T. Kamura, R.C. Conaway, J.W. Conaway, and W.G. Kaelin Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2 Mol. Cell. Biol. 18 1998 732 741
15. D.R. Duan, J.S. Humphrey, D.Y.T. Chen, Y. Weng, J. Sukegawa, S. Lee, J.R. Gnarra, W.M. Linehan, and R.D. Klausner Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations Proc. Natl. Acad. Sci. USA 92 1995 6495 6499
16. D.R. Duan, A. Pause, W. Burgress, T. Aso, D.Y.T. Chen, K.P. Garrett, R.C. Conaway, J.W. Conaway, W.M. Linehan, and R.D. Klausner Inhibition of transcriptional elongation by the VHL tumor suppressor protein Science 269 1995 1402 1406
17. T. Kishida, T.M. Stackhouse, F. Chen, M.I. Lerman, and B. Zbar Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations Cancer Res. 55 1995 4544 4548
18. T. Kamura, D.M. Koepp, M.N. Conrad, D. Skowyra, R.J. Moreland, O. Iliopoulos, W.S. Lane, W.G.J. Kaelin, S.J. Elledge, R.C. Conaway, J.W. Harper, and J.W. Conaway Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase Science 284 1999 657 661
19. A. Pause, S. Lee, R.A. Worrell, D.Y.T. Chen, W.H. Burgess, W.M. Linehan, and R.D. Klausner The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins Proc. Natl. Acad. Sci. USA 94 1997 2156 2161
20. J. Lisztwan, G. Imbert, C. Wirbelauer, M. Gstaiger, and W. Krek The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity Genes Dev. 13 1999 1822 1833
21. K. Iwai, K. Yamanaka, T. Kamura, N. Minato, R. Conaway, J. Conaway, R. Klausner, and A. Pause Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex Proc. Natl. Acad. Sci. USA 96 1999 12436 12441
22. C.E. Stebbins, W.G. Kaelin, and N.P. Pavletich Structure of the VHL-elonginC-elonginB complex: implications for VHL tumor suppressor function Science 284 1999 455 461
23. C. Bai, P. Sen, K. Hofmann, L. Ma, M. Goebl, J.W. Harper, and S.J. Elledge SKP1 connects cell cycle regulators to he ubiquitin proteolysis machinery through a novel motif, the F-box Cell 86 1996 263 274
24. M. Ohh, Y. Takagi, T. Aso, C. Stebbins, N. Pavletich, B. Zbar, R. Conaway, J. Conaway, and W.J. Kaelin Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein J. Clin. Invest. 104 1999 1583 1591
25. D.W. Golde, and W.G. Hocking Polycythemia: mechanisms and management Ann. Intern. Med. 95 1981 71 87
26. L. Brown, B. Berse, R. Jackman, K. Tognazzi, E. Manseau, H. Dvorak, and D. Senger Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas Am. J. Pathol. 143 1993 1255 1262
27. K. Sato, K. Terada, T. Sugiyama, S. Takahashi, M. Saito, M. Moriyama, H. Kakinuma, Y. Suzuki, M. Kato, and T. Kato Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma Tohoku J. Exp. Med. 173 1994 355 360
28. A. Takahashi, H. Sasaki, S. Kim, K. Tobisu, T. Kakizoe, T. Tsukamoto, Y. Kumamoto, T. Sugimura, and M. Terada Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis Cancer Res. 54 1994 4233 4237
29. K. Morii, R. Tanaka, K. Washiyama, T. Kumanishi, and R. Kuwano Expression of vascular endothelial growth factor in capillary hemangioblastoma Biochem. Biophys. Res. Commun. 194 1993 749 755
30. S. Wizigmann-Voos, G. Breier, W. Risau, and K. Plate Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas Cancer Res. 55 1995 1358 1364
31. O. Iliopoulos, C. Jiang, A.P. Levy, W.G. Kaelin, and M.A. Goldberg Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proc. Natl. Acad. Sci. USA 93 1996 10595 10599
32. G. Siemeister, K. Weindel, K. Mohrs, B. Barleon, G. Martiny-Baron, and D. Marme Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein Cancer Research 56 1996 2299 2301
33. R. Stratmann, M. Krieg, R. Haas, and K. Plate Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene J. Neuropathol. Exp. Neurol. 56 1997 1242 1252
34. G. Semenza HIF-1 and human disease: one highly involved factor Genes Dev. 14 2000 1983 1991
35. C.J. Schofield, and P.J. Ratcliffe Oxygen sensing by HIF hydroxylases Nat. Rev. Mol. Cell Biol. 5 2004 343 354
36. Y. Makino, R. Cao, K. Svensson, G. Bertilsson, M. Asman, H. Tanaka, Y. Cao, A. Berkenstam, and L. Poellinger Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression Nature 414 2001 550 554
37. Y. Makino, A. Kanopka, W.J. Wilson, H. Tanaka, and L. Poellinger Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus J. Biol. Chem. 277 2002 32405 32408
38. K.L. Talks, H. Turley, K.C. Gatter, P.H. Maxwell, C.W. Pugh, P.J. Ratcliffe, and A.L. Harris The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages Am. J. Pathol. 157 2000 411 421
39. M.S. Wiesener, J.S. Jurgensen, C. Rosenberger, C.K. Scholze, J.H. Horstrup, C. Warnecke, S. Mandriota, I. Bechmann, U.A. Frei, C.W. Pugh, P.J. Ratcliffe, S. Bachmann, P.H. Maxwell, and K.U. Eckardt Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs FASEB J. 17 2003 271 273
40. 2 homeostasis by hypoxia-inducible factor 1 Annu. Rev. Cell Dev. Biol. 15 1999 551 578
41. J. Brugarolas, K. Lei, R.L. Hurley, B.D. Manning, J.H. Reiling, E. Hafen, L.A. Witters, L.W. Ellisen, and W.G. Kaelin Jr. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex Genes Dev. 18 2004 2893 2904
42. J.H. Reiling, and E. Hafen The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila Genes Dev. 18 2004 2879 2892
43. V. Wang, D.A. Davis, M. Haque, L.E. Huang, and R. Yarchoan Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells Cancer Res. 65 2005 3299 3306
44. C.J. Hu, L.Y. Wang, L.A. Chodosh, B. Keith, and M.C. Simon Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation Mol. Cell. Biol. 23 2003 9361 9374
45. R.R. Raval, K.W. Lau, M.G. Tran, H.M. Sowter, S.J. Mandriota, J.L. Li, C.W. Pugh, P.H. Maxwell, A.L. Harris, and P.J. Ratcliffe Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma Mol. Cell. Biol. 25 2005 5675 5686
46. C. Pugh, J. O'Rourke, M. Nagao, J. Gleadle, and P. Ratcliffe Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit J. Biol. Chem. 272 1997 11205 11214
47. 2-dependent degradation domain via the ubiquitin-proteasome pathway Proc. Natl. Acad. Sci. USA 95 1998 7987 7992
48. P. Kallio, W. Wilson, S. O'Brien, Y. Makino, and L. Poellinger Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway J. Biol. Chem. 274 1999 6519 6525
49. S. Salceda, and J. Caro Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes J. Biol. Chem. 272 1997 22642 22647
50. C.H. Sutter, E. Laughner, and G.L. Semenza Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations Proc. Natl. Acad. Sci. USA 97 2000 4748 4753
51. P. Maxwell, M. Weisner, G.-W. Chang, S. Clifford, E. Vaux, C. Pugh, E. Maher, and P. Ratcliffe The von Hippel-Lindau gene product is necessary for oxygen-dependent proteolysis of hypoxia-inducible factor α subunits Nature 399 1999 271 275
52. M. Ohh, C.W. Park, M. Ivan, M.A. Hoffman, T.-Y. Kim, L.E. Huang, V. Chau, and W.G. Kaelin Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein beta domain Nat. Cell Biol. 2 2000 423 427
53. M. Cockman, N. Masson, D. Mole, P. Jaakkola, G. Chang, S. Clifford, E. Maher, C. Pugh, P. Ratcliffe, and P. Maxwell Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J. Biol. Chem. 275 2000 25733 25741
54. T. Kamura, S. Sato, K. Iwain, M. Czyzyk-Krzeska, R.C. Conaway, and J.W. Conaway Activation of hif1a ubiquitination by a reconstituted von Hippel-Lindau tumor suppressor complex Proc. Natl. Acad. Sci. USA 97 2000 10430 10435
55. K. Tanimoto, Y. Makino, T. Pereira, and L. Poellinger Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein EMBO J. 19 2000 4298 4309
56. 2 sensing Science 292 2001 464 468
57. 2-regulated prolyl hydroxylation Science 292 2001 468 472
58. N. Masson, C. Willam, P. Maxwell, C. Pugh, and P. Ratcliffe Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroylation EMBO J. 20 2001 5197 5206
59. W.C. Hon, M.I. Wilson, K. Harlos, T.D. Claridge, C.J. Schofield, C.W. Pugh, P.H. Maxwell, P.J. Ratcliffe, D.I. Stuart, and E.Y. Jones Structural basis for the recognition of hydroxyproline in HIF-1alpha by pVHL Nature 2002
60. J.H. Min, H. Yang, M. Ivan, F. Gertler, W.G. Kaelin Jr., and N.P. Pavletich Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling Science 296 2002 1886 1889
61. F. Yu, S. White, Q. Zhao, and F. Lee HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation Proc. Natl. Acad. Sci. USA 98 2001 9630 9635
62. F. Yu, S. White, Q. Zhao, and F. Lee Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein Cancer Res. 61 2001 4136 4142
63. A. Epstein, J. Gleadle, L. McNeill, K. Hewitson, J. O'Rourke, D. Mole, M. Mukherji, E. Metzen, M. Wilson, A. Dhanda, Y. Tian, N. Masson, D. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P. Maxwell, C. Pugh, C. Schofield, and P. Ratcliffe C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 2001 43 54
64. R. Bruick, and S. McKnight A conserved family of prolyl-4-hydroxylases that modify HIF Science 294 2001 1337 1340
65. M. Ivan, T. Haberberger, D.C. Gervasi, K.S. Michelson, V. Gunzler, K. Kondo, H. Yang, I. Sorokina, R.C. Conaway, J.W. Conaway, and W.G. Kaelin Jr. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor Proc. Natl. Acad. Sci. USA 99 2002 13459 13464
66. M.S. Taylor Characterization and comparative analysis of the EGLN gene family Gene 275 2001 125 132
67. L. Aravind, and E.V. Koonin The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases Genome Bio. 2 2001 research0007.0001-0007.0008
68. M. Hirsila, P. Koivunen, V. Gunzler, K.I. Kivirikko, and J. Myllyharju Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor J. Biol. Chem. 278 2003 30772 30780
69. E. Berra, E. Benizri, A. Ginouves, V. Volmat, D. Roux, and J. Pouyssegur HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia EMBO J. 22 2003 4082 4090
70. L. del Peso, M.C. Castellanos, E. Temes, S. Martin-Puig, Y. Cuevas, G. Olmos, and M.O. Landazuri The von Hippel-Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen J. Biol. Chem. 278 2003 48690 48695
71. R.J. Appelhoff, Y.M. Tian, R.R. Raval, H. Turley, A.L. Harris, C.W. Pugh, P.J. Ratcliffe, and J.M. Gleadle Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor J. Biol. Chem. 279 2004 38458 38465
72. O. Aprelikova, G.V. Chandramouli, M. Wood, J.R. Vasselli, J. Riss, J.K. Maranchie, W.M. Linehan, and J.C. Barrett Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors J. Cell Biochem. 92 2004 491 501
73. C.L. Cioffi, X.Q. Liu, P.A. Kosinski, M. Garay, and B.R. Bowen Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells Biochem. Biophys. Res. Commun. 303 2003 947 953
74. J.K. Brunelle, E.L. Bell, N.M. Quesada, K. Vercauteren, V. Tiranti, M. Zeviani, R.C. Scarpulla, and N.S. Chandel Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation Cell Metab. 1 2005 409 414
75. K.D. Mansfield, R.D. Guzy, Y. Pan, R.M. Young, T.P. Cash, P.T. Schumacher, and M.C. Simon Loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-a activation Cell Metab. 1 2005 393 399
76. R.D. Guzy, B. Hoyos, E. Robin, H. Chen, L. Liu, K.D. Mansfield, M.C. Simon, U. Hammerling, and P.T. Schumacker Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing Cell Metab. 1 2005 401 408
77. D.A. Chan, P.D. Sutphin, N.C. Denko, and A.J. Giaccia Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha J. Biol. Chem. 277 2002 40112 40117
78. D. Gerald, E. Berra, Y.M. Frapart, D.A. Chan, A.J. Giaccia, D. Mansuy, J. Pouyssegur, M. Yaniv, and F. Mechta-Grigoriou JunD reduces tumor angiogenesis by protecting cells from oxidative stress Cell 118 2004 781 794
79. W.G. Kaelin Proline hydroxylation and gene expression Annu. Rev. Biochem. 74 2005 115 128
80. Y. Liu, H. Christou, T. Morita, E. Laughner, G. Semenza, and S. Kourembanas Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhancer J. Biol. Chem. 273 1998 15257 15262
81. K. Sogawa, K. Numayama-Tsuruta, M. Ema, M. Abe, H. Abe, and Y. Fujii-Kuriyama Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia Proc. Natl. Acad. Sci. USA 95 1998 7368 7373
82. L. Huang, W. Willmore, J. Gu, M. Goldberg, and H. Bunn Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling J. Biol. Chem. 274 1999 9038 9044
83. L.A. Palmer, B. Gaston, and R.A. Johns Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides Mol. Pharmacol. 58 2000 1197 1203
84. K.B. Sandau, J. Fandrey, and B. Brune Accumulation of HIF-1alpha under the influence of nitric oxide Blood 97 2001 1009 1015
85. F.H. Agani, M. Puchowicz, J.C. Chavez, P. Pichiule, and J. LaManna Role of nitric oxide in the regulation of HIF-1alpha expression during hypoxia Am. J. Physiol. Cell Physiol. 283 2002 C178 C186
86. F. Wang, H. Sekine, Y. Kikuchi, C. Takasaki, C. Miura, O. Heiwa, T. Shuin, Y. Fujii-Kuriyama, and K. Sogawa HIF-1alpha-prolyl hydroxylase: molecular target of nitric oxide in the hypoxic signal transduction pathway Biochem. Biophys. Res. Commun. 295 2002 657 662
87. T. Hagen, C.T. Taylor, F. Lam, and S. Moncada Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha Science 302 2003 1975 1978
88. E. Metzen, J. Zhou, W. Jelkmann, J. Fandrey, and B. Brune Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases Mol. Biol. Cell 14 2003 3470 3481
89. B.H. Jiang, J.Z. Zheng, S.W. Leung, R. Roe, and G.L. Semenza Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension J. Biol. Chem. 272 1997 19253 19260
90. P.J. Kallio, K. Okamoto, S. O'Brien, P. Carrero, Y. Makino, H. Tanaka, and L. Poellinger Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha EMBO J. 17 1998 6573 6586
91. M. Ema, K. Hirota, J. Mimura, H. Abe, J. Yodoi, K. Sogawa, L. Poellinger, and Y. Fujii-Kuriyama Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300 EMBO J. 18 1999 1905 1914
92. J.F. O'Rourke, Y.M. Tian, P.J. Ratcliffe, and C.W. Pugh Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha J. Biol. Chem. 274 1999 2060 2071
93. P. Carrero, K. Okamoto, P. Coumailleau, S. O'Brien, H. Tanaka, and L. Poellinger Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha Mol. Cell. Biol. 20 2000 402 415
94. P. Mahon, K. Hirota, and G. Semenza FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity Genes and Dev. 15 2001 2675 2686
95. K.S. Hewitson, L.A. McNeill, M.V. Riordan, Y.M. Tian, A.N. Bullock, R.W. Welford, J.M. Elkins, N.J. Oldham, S. Bhattacharya, J.M. Gleadle, P.J. Ratcliffe, C.W. Pugh, and C.J. Schofield Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family J. Biol. Chem. 277 2002 26351 26355
96. D. Lando, D. Peet, J. Gorman, D. Whelan, M. Whitelaw, and R. Bruick FIH-1 is a an asparaginyl hydroxylase that regulates the transcriptional activity of hypoxia inducible factor Genes Dev. 2002
97. J.M. Elkins, K.S. Hewitson, L.A. McNeill, J.F. Seibel, I. Schlemminger, C.W. Pugh, P.J. Ratcliffe, and C.J. Schofield Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha J. Biol. Chem. 278 2003 1802 1806
98. P. Koivunen, M. Hirsila, V. Gunzler, K.I. Kivirikko, and J. Myllyharju Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases J. Biol. Chem. 279 2004 9899 9904
99. I.P. Stolze, Y.M. Tian, R.J. Appelhoff, H. Turley, C.C. Wykoff, J.M. Gleadle, and P.J. Ratcliffe Genetic analysis of the role of the asparaginyl hydroxylase FIH in regulating HIF transcriptional target genes J. Biol. Chem. 2004
100. S. Dames, M. Martinez-Yamout, R. De Guzman, H. Dyson, and P. Wright From the cover: structural basis for Hif-1alpha/CBP recognition in the cellular hypoxic response Proc. Natl. Acad. Sci. USA 99 2002 5271 5276
101. S. Freedman, Z. Sun, F. Poy, A. Kung, D. Livingston, G. Wagner, and M. Eck Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1alpha Proc. Natl. Acad. Sci. USA 99 2002 5367 5372
102. J.W. Jeong, M.K. Bae, M.Y. Ahn, S.H. Kim, T.K. Sohn, M.H. Bae, M.A. Yoo, E.J. Song, K.J. Lee, and K.W. Kim Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation Cell 111 2002 709 720
103. R. Bilton, N. Mazure, E. Trottier, M. Hattab, M.A. Dery, D.E. Richard, J. Pouyssegur, and M.C. Brahimi-Horn ARD1, an acetyltransferase, does not alter stability of hypoxia-inducible factor-1alpha and is not induced by hypoxia or HIF J. Biol. Chem. 2005
104. T.S. Fisher, S.D. Etages, L. Hayes, K. Crimin, and B. Li Analysis of ARD1 function in hypoxia response using retroviral RNA interference J. Biol. Chem. 280 2005 17749 17757
105. S.H. Bae, J.W. Jeong, J.A. Park, S.H. Kim, M.K. Bae, S.J. Choi, and K.W. Kim Sumoylation increases HIF-1alpha stability and its transcriptional activity Biochem. Biophys. Res. Commun. 324 2004 394 400
106. R. Shao, F.P. Zhang, F. Tian, P. Anders Friberg, X. Wang, H. Sjoland, and H. Billig Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse brain and heart in vivo FEBS Lett. 569 2004 293 300
107. H. Ryan, J. Lo, and R. Johnson HIF-1α is required for solid tumor formation and embryonic vascularization EMBO J. 17 1998 3005 3015
108. P. Carmeliet, Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C.J. Koch, P. Ratcliffe, L. Moons, R.K. Jain, D. Collen, E. Keshert, and E. Keshet Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis Nature 394 1998 485 490
109. P. Maxwell, G. Dachs, J. Gleadle, L. Nicholls, A. Harris, I. Stratford, O. Hankinson, C. Pugh, and P. Ratcliffe Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc. Natl. Acad. Sci. USA 94 1997 8104 8109
110. H. Zhong, A. De Marzo, E. Laughner, M. Lim, D. Hilton, D. Zagzag, P. Buechler, W. Isaacs, G. Semenza, and J. Simons Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res. 59 1999 5830 5835
111. S. Richard, C. Campello, L. Taillandier, F. Parker, and F. Resche Haemangioblastoma of the central nervous system in von Hippel-Lindau disease J. Intern. Med. 243 1998 547 553
112. L.E. Benjamin, and E. Keshet Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal Proc. Natl. Acad. Sci. USA 94 1997 8761 8766
113. E.J. Rebar, Y. Huang, R. Hickey, A.K. Nath, D. Meoli, S. Nath, B. Chen, L. Xu, Y. Liang, A.C. Jamieson, L. Zhang, S.K. Spratt, C.C. Case, A. Wolffe, and F.J. Giordano Induction of angiogenesis in a mouse model using engineered transcription factors Nat. Med. 8 2002 1427 1432
114. T. Bohling, E. Hatva, M. Kujala, L. Claesson-Welsh, K. Alitalo, and M. Haltia Expression of growth factors and growth factor receptors in capillary hemangioblastoma J. Neuropathol. Exp. Neurol. 55 1996 522 527
115. B. Knebelmann, S. Ananth, H. Cohen, and V. Sukhatme Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor Cancer Res. 58 1998 226 231
116. A.O. Vortmeyer, S. Frank, S.Y. Jeong, K. Yuan, B. Ikejiri, Y.S. Lee, D. Bhowmick, R.R. Lonser, R. Smith, G. Rodgers, E.H. Oldfield, and Z. Zhuang Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease Cancer Res. 63 2003 7051 7055
117. D. Zagzag, B. Krishnamachary, H. Yee, H. Okuyama, L. Chiriboga, M.A. Ali, J. Melamed, and G.L. Semenza Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor Cancer Res. 65 2005 6178 6188
118. S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, and P.M. Comoglio Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
119. S. Ananth, B. Knebelmann, W. Gruning, M. Dhanabal, G. Walz, I. Stillman, and V. Sukhatme Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma Cancer Res. 59 1999 2210 2216
120. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E.J. Oakeley, and W. Krek Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL Nature 425 2003 307 311
121. S. Koochekpour, M. Jeffers, P. Wang, C. Gong, G. Taylor, L. Roessler, R. Stearman, J. Vasselli, W. Stetler-Stevenson, W.J. Kaelin, W. Linehan, R. Klausner, J. Gnarra, and G. VandeWoude The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells Mol. Cell. Biol. 19 1999 5902 5912
122. B.L. Petrella, J. Lohi, and C.E. Brinckerhoff Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma Oncogene 24 2005 1043 1052
123. S.J. Mandriota, K.J. Turner, D.R. Davies, P.G. Murray, N.V. Morgan, H.M. Sowter, C.C. Wykoff, E.R. Maher, A.L. Harris, P.J. Ratcliffe, and P.H. Maxwell HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron Cancer Cell 1 2002 459 468
124. K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, and W.G. Kaelin Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 2002 237 246
125. K. Kondo, W.Y. Kim, M. Lechpammer, and W.G. Kaelin Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol. 1 2003 E83
126. -/- tumors Mol. Cancer Res. 2 2004 89 95
127. -/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis Proc. Natl. Acad. Sci. USA 13 2001 1387 1392
128. -/- renal cancer Cancer Res. 65 2005 5221 5230
129. M. Zatyka, N.F. da Silva, S.C. Clifford, M.R. Morris, M.S. Wiesener, K.U. Eckardt, R.S. Houlston, F.M. Richards, F. Latif, and E.R. Maher Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease Cancer Res. 62 2002 3803 3811
130. M. Baba, S. Hirai, H. Yamada-Okabe, K. Hamada, H. Tabuchi, K. Kobayashi, K. Kondo, M. Yoshida, A. Yamashita, T. Kishida, N. Nakaigawa, Y. Nagashima, Y. Kubota, M. Yao, and S. Ohno Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor Oncogene 22 2003 2728 2738
131. R.S. Bindra, J.R. Vasselli, R. Stearman, W.M. Linehan, and R.D. Klausner VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells Cancer Res. 62 2002 3014 3019
132. C. Wykoff, C. Pugh, P. Maxwell, A. Harris, and P. Ratcliffe Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling Oncogene 19 2000 6297 6305
133. A. Kung, S. Wang, J. Klco, W. Kaelin, and D. Livingston Suppression of tumor growth through disruption of hypoxia-inducible transcription Nat. Med. 6 2000 1335 1340
134. A.L. Kung, S.D. Zabludoff, D.S. France, S.J. Freedman, E.A. Tanner, A. Vieira, S. Cornell-Kennon, J. Lee, B. Wang, J. Wang, K. Memmert, H.U. Naegeli, F. Petersen, M.J. Eck, K.W. Bair, A.W. Wood, and D.M. Livingston Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway Cancer Cell 6 2004 33 43
135. B.Z. Olenyuk, G.J. Zhang, J.M. Klco, N.G. Nickols, W.G. Kaelin Jr., and P.B. Dervan Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist Proc. Natl. Acad. Sci. USA 101 2004 16768 16773
136. C.C. Hudson, M. Liu, G.G. Chiang, D.M. Otterness, D.C. Loomis, F. Kaper, A.J. Giaccia, and R.T. Abraham Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol. Cell. Biol. 22 2002 7004 7014
137. H. Zhong, K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M.M. Georgescu, J.W. Simons, and G.L. Semenza Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics Cancer Res. 60 2000 1541 1545
138. J.B. Brugarolas, F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways Cancer Cell 4 2003 147 158
139. J.S. Isaacs, Y.J. Jung, E.G. Mimnaugh, A. Martinez, F. Cuttitta, and L.M. Neckers Hsp90 regulates a von Hippel-Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway J. Biol. Chem. 277 2002 29936 29944
140. N.J. Mabjeesh, D.E. Post, M.T. Willard, B. Kaur, E.G. Van Meir, J.W. Simons, and H. Zhong Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells Cancer Res. 62 2002 2478 2482
141. M.S. Kim, H.J. Kwon, Y.M. Lee, J.H. Baek, J.E. Jang, S.W. Lee, E.J. Moon, H.S. Kim, S.K. Lee, H.Y. Chung, C.W. Kim, and K.W. Kim Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes Nat. Med. 7 2001 437 443
142. P. Atadja, M. Hsu, P. Kwon, N. Trogani, K. Bhalla, and S. Remiszewski Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824 Novartis Found. Symp. 259 2004 249 266 discussion 266-248, 285-248
143. S.J. Welsh, R.R. Williams, A. Birmingham, D.J. Newman, D.L. Kirkpatrick, and G. Powis The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl
144. S. Welsh, R. Williams, L. Kirkpatrick, G. Paine-Murrieta, and G. Powis Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha Mol. Cancer Ther. 3 2004 233 244
145. N.J. Mabjeesh, D. Escuin, T.M. LaVallee, V.S. Pribluda, G.M. Swartz, M.S. Johnson, M.T. Willard, H. Zhong, J.W. Simons, and P. Giannakakou 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 3 2003 363 375
146. Y.J. Jung, J.S. Isaacs, S. Lee, J. Trepel, and L. Neckers Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein J. Biol. Chem. 278 2003 7445 7452
147. W.G. Kaelin Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer Clin. Cancer Res. 10 2004 6290S 6295S
148. L.P. Aiello, D.J. George, M.T. Cahill, J.S. Wong, J. Cavallerano, A.L. Hannah, and W.G. Kaelin Jr. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416 Ophthalmology 109 2002 1745 1751
149. S. Richard, L. Croisille, J. Yvart, N. Casadeval, P. Eschwege, N. Aghakhani, P. David, A. Gaudric, P. Scigalla, and O. Hermine Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy Blood 99 2002 3851 3853
150. J.F. Girmens, A. Erginay, P. Massin, P. Scigalla, A. Gaudric, and S. Richard Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas Am. J. Ophthalmol. 136 2003 194 196
151. S. Madhusudan, G. Deplanque, J.P. Braybrooke, E. Cattell, M. Taylor, P. Price, M.D. Tsaloumas, N. Moore, S.M. Huson, C. Adams, P. Frith, P. Scigalla, and A.L. Harris Antiangiogenic therapy for von Hippel-Lindau disease JAMA 291 2004 943 944
152. I. Schlemminger, D.R. Mole, L.A. McNeill, A. Dhanda, K.S. Hewitson, Y.M. Tian, P.J. Ratcliffe, C.W. Pugh, and C.J. Schofield Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases Bioorg. Med. Chem. Lett. 13 2003 1451 1454
153. T.M. Asikainen, A. Ahmad, B.K. Schneider, W.B. Ho, M. Arend, M. Brenner, V. Gunzler, and C.W. White Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells Free Radic. Biol. Med. 38 2005 1002 1013
154. T.M. Asikainen, B.K. Schneider, N.S. Waleh, R.I. Clyman, W.B. Ho, L.A. Flippin, V. Gunzler, and C.W. White Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung Proc. Natl. Acad. Sci. USA 102 2005 10212 10217
155. M.A. McDonough, L.A. McNeill, M. Tilliet, C.A. Papamicael, Q.Y. Chen, B. Banerji, K.S. Hewitson, and C.J. Schofield Selective inhibition of factor inhibiting hypoxia-inducible factor J. Am. Chem. Soc. 127 2005 7680 7681
156. T. Date, S. Mochizuki, A.J. Belanger, M. Yamakawa, Z. Luo, K.A. Vincent, S.H. Cheng, R.J. Gregory, and C. Jiang Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury Am. J. Physiol. Cell Physiol. 288 2005 C314 C320
157. R.R. Ratan, A. Siddiq, L. Aminova, P.S. Lange, B. Langley, I. Ayoub, J. Gensert, and J. Chavez Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy Stroke 35 2004 2687 2689
158. Z. Cai, D.J. Manalo, G. Wei, E.R. Rodriguez, K. Fox-Talbot, H. Lu, J.L. Zweier, and G.L. Semenza Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury Circulation 108 2003 79 85
159. M. Bergeron, J.M. Gidday, A.Y. Yu, G.L. Semenza, D.M. Ferriero, and F.R. Sharp Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain Ann. Neurol. 48 2000 285 296
160. M. Matsumoto, Y. Makino, T. Tanaka, H. Tanaka, N. Ishizaka, E. Noiri, T. Fujita, and M. Nangaku Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats J. Am. Soc. Nephrol. 14 2003 1825 1832
161. C. Rosenberger, S.N. Heyman, S. Rosen, A. Shina, M. Goldfarb, W. Griethe, U. Frei, P. Reinke, S. Bachmann, and K.U. Eckardt Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia Kidney Int. 67 2005 531 542
162. J.I. Nwogu, D. Geenen, M. Bean, M.B. Brenner, X. Huang, and P.M. Buttrick Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilation after myocardial infarction Circulation 104 2001 2216 2221
163. K.G. Shyu, M.T. Wang, B.W. Wang, C.C. Chang, J.G. Leu, P. Kuan, and H. Chang Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat Cardiovasc. Res. 54 2002 576 583
164. M.F. Czyzyk-Krzeska, and J. Meller Von Hippel-Lindau tumor suppressor: not only HIF's executioner Trends Mol. Med. 10 2004 146 149
165. T. Bishop, K.W. Lau, A.C. Epstein, S.K. Kim, M. Jiang, D. O'Rourke, C.W. Pugh, J.M. Gleadle, M.S. Taylor, J. Hodgkin, and P.J. Ratcliffe Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans PLoS Biol. 2 2004 e289
166. M. Hoffman, M. Ohh, H. Yang, J. Klco, M. Ivan, and W.J. Kaelin von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Hum. Mol. Genet. 10 2001 1019 1027
167. W.G. Kaelin Molecular basis of the VHL hereditary cancer syndrome Nat. Rev. Cancer 2 2002 673 682
168. S. Clifford, M. Cockman, A. Smallwood, D. Mole, E. Woodward, P. Maxwell, P. Ratcliffe, and E. Maher Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease Hum. Mol. Genet. 10 2001 1029 1038
169. D. Elson, G. Thurston, L. Huang, D. Ginzinger, D. McDonald, R. Johnson, and J. Arbeit Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α Genes Dev. 2001 2520 2532
170. K. Vincent, K. Shyu, Y. Luo, M. Magner, R. Tio, C. Jiang, M. Goldberg, G. Akita, R. Gregory, and J. Isner Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor Circulation 102 2000 2255 2261
171. I.A. Lubensky, J.R. Gnarra, P. Bertheau, M.M. Walther, W.M. Linehan, and Z. Zhuang Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients Am. J. Pathol. 149 1996 2089 2094
172. Z. Zhuang, P. Bertheau, M. Emmert-Buck, L. Liotta, J. Gnarra, W. Linehan, and I. Lubensky A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size Am. J. Pathol. 146 1995 620 625
173. S.O. Ang, H. Chen, K. Hirota, V.R. Gordeuk, J. Jelinek, Y. Guan, E. Liu, A.I. Sergueeva, G.Y. Miasnikova, D. Mole, P.H. Maxwell, D.W. Stockton, G.L. Semenza, and J.T. Prchal Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia Nat. Genet. 32 2002 614 621
174. V.R. Gordeuk, A.I. Sergueeva, G.Y. Miasnikova, D. Okhotin, Y. Voloshin, P.L. Choyke, J.A. Butman, K. Jedlickova, J.T. Prchal, and L.A. Polyakova Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors Blood 103 2004 3924 3932
175. F. Chen, T. Kishida, M. Yao, T. Hustad, D. Glavac, M. Dean, J.R. Gnarra, M.L. Orcutt, F.M. Duh, G. Glenn, J. Green, Y.E. Hsia, J. Lamiell, H.W. Ming, L. Schmidt, T. Kalman, I. Kuzmin, T. Stackhouse, F. Latif, W.M. Linehan, M. Lerman, and B. Zbar Germline mutations in the von Hippel-Lindau disease tumor suppressor gene:correlations with phenotype Hum. Mutat. 5 1995 66 75
176. P. Crossey, K. Foster, F. Richards, M. Phipps, F. Latif, K. Tory, M. Jones, E. Bentley, R. Kumar, M. Lerman, B. Zbar, N. Affara, M. Ferguson-Smith, and E. Maher Molecular genetic investigation of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours Hum. Genet. 93 1994 53 58
177. M.A. Zeiger, B. Zbar, H. Keiser, W.M. Linehan, and J.R. Gnarra Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma Genes Chromosomes Cancer 13 1995 151 156
178. B. Bender, M. Gutsche, S. Glasker, B. Muller, G. Kirste, C. Eng, and H. Neumann Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas J. Clin. Endocrinol. Metab. 85 2000 4568 4574
179. A. Prowse, A. Webster, F. Richards, S. Richard, S. Olschwang, F. Resche, N. Affara, and E. Maher Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors Am. J. Hum. Genet. 60 1997 761 765
180. J. Bryant, J. Farmer, L.J. Kessler, R.R. Townsend, and K.L. Nathanson Pheochromocytoma: the expanding genetic differential diagnosis J. Natl. Cancer Inst. 95 2003 1196 1204
181. E.R. Maher, and C. Eng The pressure rises: update on the genetics of phaeochromocytoma Hum. Mol. Genet. 11 2002 2347 2354
182. S. Estus, W.J. Zaks, R.S. Freeman, M. Gruda, R. Bravo, and E.M. Johnson Jr. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis J. Cell Biol. 127 1994 1717 1727
183. K.H. Schlingensiepen, F. Wollnik, M. Kunst, R. Schlingensiepen, T. Herdegen, and W. Brysch The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo Cell Mol. Neurobiol. 14 1994 487 505
184. J. Ham, C. Babij, J. Whitfield, C.M. Pfarr, D. Lallemand, M. Yaniv, and L.L. Rubin A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death Neuron 14 1995 927 939
185. Z. Xia, M. Dickens, J. Raingeaud, R.J. Davis, and M.E. Greenberg Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 1995 1326 1331
186. K.S. Vogel, C.I. Brannan, N.A. Jenkins, N.G. Copeland, and L.F. Parada Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons Cell 82 1995 733 742
187. B.A. Tsui-Pierchala, J. Milbrandt, and E.M. Johnson Jr. NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons Neuron 33 2002 261 273
188. G. Dechant Chat in the trophic web: NGF activates Ret by inter-RTK signaling Neuron 33 2002 156 158
189. S. Lee, E. Nakamura, H. Yang, W. Wei, M. Linggi, M. Sajan, R. Farese, F. RS, B. Carter, W. Kaelin, and S. Schlisio Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental Culling and Cancer Cancer Cell 8 2005 155 167
190. H. Okuda, K. Saitoh, S. Hirai, K. Iwai, Y. Takaki, M. Baba, N. Minato, S. Ohno, and T. Shuin The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C J. Biol. Chem. 276 2001 43611 43617
191. S. Pal, K. Claffey, H. Dvorak, and D. Mukhopadhyay The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways J. Biol. Chem. 272 1997 27509 27512
192. S. Pal, K. Claffey, H. Cohen, and D. Mukhopadhyay Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase Cζ J. Biol. Chem. 273 1998 26277 26280
193. A. Kieser, T. Seitz, H.S. Adler, P. Coffer, E. Kremmer, P. Crespo, J.S. Gutkind, D.W. Henderson, J.F. Mushinski, W. Kolch, and H. Mischak Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells Genes Dev. 10 1996 1455 1466
194. E. Lipscomb, P. Sarmiere, R. Crowder, and R. Freeman Expression of the SM-20 gene promotes death in nerve growth factor-dependent sympathetic neurons J. Neurochem. 73 1999 429 432
195. E. Lipscomb, P. Sarmiere, and R. Freeman SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons J. Biol. Chem. 276 2001 11775 11782
196. J.A. Straub, E.A. Lipscomb, E.S. Yoshida, and R.S. Freeman Induction of SM-20 in PC12 cells leads to increased cytochrome c levels, accumulation of cytochrome c in the cytosol, and caspase-dependent cell death J. Neurochem. 85 2003 318 328